IDDF2018-ABS-0221 Maintenance with faecal microbiota transplantation enhances deep remission in patients with ulcerative colitis in clinical remission

    loading  Checking for direct PDF access through Ovid



Faecal microbiota transplantation (FMT) is beneficial in patients with active ulcerative colitis (UC), but its role in the maintenance of clinical remission and mucosal healing has not been assessed.


This was a prospective, double-blind, randomised placebo-controlled trial conducted at Dayanand Medical College and Hospital, India. Twenty-eight patients with UC in clinical remission (Mayo Score=1) and histological remission (Nancy grade 0, 1) at 48 weeks.


Twenty-eight patients (50% males, aged 37.21±15.25 years) with UC in clinical remission were randomised to groups A and B. At the end of 48 weeks, none of the patients in either group suffered a clinical relapse (p=1). Deep remission was noted in significantly higher number of patients with FMT (n=12, 85.71%) when compared with placebo (n=4, 28.57%) (p=0.002). Histological remission was twice as high in patients treated with FMT (n=8, 57.14% vs placebo, n=4, 28.57%; p=0.13). Rate of endoscopic response was also higher with FMT (n=8, 57.14%) when compared to placebo (n=0, zero%) (p=0.001). No serious adverse events were noted.


Maintenance with FMT can enhance achievement of deep remission and histological remission in patients with UC in clinical remission.

Related Topics

    loading  Loading Related Articles